About: Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
Creator	Hoppe, Uta Egle, · Lichtenauer, · Lukas, · Motloch, J Paar, Vera Wernly, · Zhou, Zhichao
Source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been linked to a higher risk of mortality compared to influenza, which is mainly due to severe secondary diseases, such as acute respiratory distress syndrome (ARDS). In turn, ARDS is characterized by an acute inflammation and an excessive activity of the coagulation cascade, rising the vulnerability for venous thromboembolic events. In order to investigate the relation of inflammation and the influence of coagulation factors on their release, human peripheral mononuclear blood cells (PBMCs) were treated with autologous serum, heparinized plasma and different doses of fibrin. Thereafter, the concentration of pro-inflammatory cytokines and chemokines in the secretome of PBMCs was measured by enzyme-linked immunosorbent assay. Our analyses revealed autologous serum to significantly increase the secretion of cytokines and chemokines after 24 h of incubation time. Furthermore, the addition of fibrin markedly increased the secretion of cytokines and chemokines by PBMCs in a dose-dependent manner. Consequently, in accordance with previous studies, our study outlines that anti-coagulation may constitute a promising tool for the treatment of SARS-CoV-2, reducing both, the cytokine storm, as well as the risk for thrombotic complications.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1007/s11239-020-02212-6
bibo:pmid	32632558
has license	cc-by
sha1sum (hex)	c6cb07d9e3254ec7c5bb37e2fe855fc5900ead6c
schema:url	https://doi.org/10.1007/s11239-020-02212-6
resource representing a document's title	Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?
has PubMed Central identifier	PMC7338133
has PubMed identifier	32632558
schema:publication	J Thromb Thrombolysis
resource representing a document's body	covid:c6cb07d9e3254ec7c5bb37e2fe855fc5900ead6c#body_text
is schema:about of	named entity 'outlines' named entity 'measured' named entity 'PBMCs' named entity 'reducing' named entity 'linked' named entity 'thromboembolic events' named entity 'anti-inflammatory' named entity 'BLOOD CELLS' named entity 'INFLAMMATION' named entity 'INCREASE' named entity 'TO INVESTIGATE' named entity 'THEIR' named entity 'MONONUCLEAR' named entity 'TURN' named entity 'VULNERABILITY' named entity 'TOOL' named entity 'blood cells' named entity 'turn' named entity 'chemokines' named entity 'acute respiratory distress syndrome (ARDS)' named entity 'manner' named entity 'higher' named entity 'rising' named entity 'order' named entity 'dose-dependent' named entity 'cytokines' named entity 'incubation time' named entity 'coagulation factors' named entity 'PBMCs' named entity 'pro-inflammatory cytokines' named entity 'chemokines' named entity 'PBMCs' named entity 'venous thromboembolic events' named entity 'blood cells' named entity 'cytokines' named entity 'plasma' named entity 'ARDS' named entity 'acute respiratory distress syndrome' named entity 'COVID' named entity 'serum' named entity 'fibrin' named entity 'Creative Commons licence' named entity 'protein' named entity 'IL-7' named entity 'chemokines' named entity 'inflammation' named entity 'coagulation' named entity 'cytokine storm' named entity 'coagulation factors' named entity 'inflammatory cytokines' named entity 'thrombosis' named entity 'virus' named entity 'cytokine' named entity 'inflammation' named entity 'negative control' named entity 'SARS-CoV-2' named entity 'IFN-γ' named entity 'd-dimer' named entity 'IL-2' named entity 'Sigma-Aldrich' named entity 'd-dimer' named entity 'DIC' named entity 'inflammatory response' named entity 'DIC' named entity 'IL-10' named entity 'TNF-α' named entity 'fibrin' named entity 'PBMCs' named entity 'cardiac myocytes' named entity 'positive correlation' named entity 'coronavirus' named entity 'fibrin' named entity 'systemic inflammatory response syndrome' named entity 'proinflammatory cytokines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software